Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer

Size: px
Start display at page:

Download "Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer"

Transcription

1 Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel Fahey, BS, Sai Yendamuri, MD, Elisabeth Dexter, MD, Todd L. Demmy, MD, Austin Miller, PhD, and Mary Reid, PhD Department of Surgery, State University of New York (SUNY) at Buffalo, and Departments of Thoracic Surgery, Biostatistics and Medicine, Roswell Park Cancer Institute, Buffalo, New York Background. The non small cell lung cancer TNM classification system uses only the anatomic extent of lymph node (LN) metastases to define the N category. The number of LNs resected and the ratio of positive LNs to total examined LNs are prognostic in other solid tumors. We used the Surveillance, Epidemiology and End Results database to investigate the effect of these factors on the overall survival of non small cell lung cancer. Methods. All patients with non small cell lung cancer in the Surveillance, Epidemiology and End Results database from 1988 through 2007 who had curative resections and had at least one LN examined were included. The prognostic value of age, race, sex, tumor size, histologic grade, number of examined LNs, and ratio of positive LNs to total examined LNs was assessed using a multivariate Cox proportional hazards model for overall survival. The number of LNs examined was categorized into four levels. The percentage of positive LNs was stratified into three levels. Results. Among patients with localized disease, fewer LNs examined corresponded with a worse prognosis. Prognosis improved as more LNs were examined. For patients with regional disease, the differences were significant only at the extremes. Older patients, males, and those with higher grade or larger tumors did worse. Patients with low or moderate ratios of positive to total LNs had better prognoses than those with high ratios. Conclusions. More LNs resected and lower ratios of positive LNs to total examined LNs are associated with better patient survival after non small cell lung cancer resection independent of age, sex, grade, tumor size, and stage of disease. (Ann Thorac Surg 2012;93: ) 2012 by The Society of Thoracic Surgeons Lung cancer is the leading cause of cancer death in the United States accounting for 157,000 deaths annually [1]. Non small cell lung cancer (NSCLC) comprises about 80% of all cases. Unfortunately, only 20% of patients present with potentially surgically curable locoregional disease [2]. For these patients, lymph node (LN) metastasis is the most important prognostic factor. Survival is also influenced by age, sex, socioeconomic status, tumor size, histology, tumor grade, and type of treatment [3]. In the current lung cancer tumor-node-metastasis (TNM) staging system, the anatomic extent of LN metastases is the only factor used to define the N category of TNM [4]. However, the TNM classification system for breast, gastric, and colorectal cancer has been updated from the traditional system to include number of metastatic lymph nodes (MLNs) in the N staging. In these cancers, the number of MLNs has been shown to be a Accepted for publication Jan 23, Presented at the Fifty-eighth Annual Meeting of the Southern Thoracic Surgical Association, San Antonio, TX, Nov 9 12, Address correspondence to Dr Nwogu, Department of Thoracic Surgery, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263; address: chumy.nwogu@roswellpark.org. more effective prognostic indicator than the anatomic location of MLNs [5]. It has been suggested that the ratio of MLNs to total number of LNs examined (lymph node ratio [LNR]) in breast, bladder, gastric, colon, and rectal cancers is a better prognostic indicator than the number of MLNs [6 10]. For NSCLC, it has been reported that the number of MLNs can give a better N category prognosis than the anatomic location of MLNs, which is currently used [11]. Therefore, we used the Surveillance, Epidemiology and End Results (SEER) database to explore the prognostic value of the number of LNs examined (LNE) and the ratio of MLNs to total number of LNE. Our hypothesis was that a higher number of LNE and a lower LNR would both be associated with better overall survival and better disease-specific survival in all stages of resectable NSCLC. Material and Methods Population-based data were obtained from the SEER program. Data on resected lung cancer cases were obtained from the SEER 9 registry for the years by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur

2 Ann Thorac Surg NWOGU ET AL 2012;93: LYMPH NODE NUMBER/RATIO IN LUNG CANCER 1615 through 1992 and from the SEER 13 registry for the years 1993 through The year 1988 was selected as the starting point because the extent of LN evaluation was not uniformly available in this database until then. The details about the data collection and database are provided in the National Cancer Institute SEER Cancer Statistics Review. Because we used existing data without individual subject identification, our institutional review board waived individual informed consent. The lung cancers included International Classification of Diseases codes C33.0 through C34.9 and C39.0 through C Small cell lung cancers were excluded. The study sample was restricted to patients undergoing curative resections (lobectomy, bilobectomy, and pneumonectomy) who had at least one LNE. This included patients with both localized and regional disease (stages I, II, and III). Localized disease was defined as a single tumor confined to the lung. Regional disease included disease that extended to the chest wall, diaphragm, and mediastinal structures or involved ipsilateral regional LNs. It also included separate tumor nodules in the same lobe. American Joint Committee on Cancer TNM staging information was available for patients diagnosed in 2004 or later. Patients who received radiation therapy were excluded because such treatment may have been administered in the adjuvant setting as a result of positive or close surgical margins. Based on the distribution of patients in our cohort (quartiles), the number of LNE was categorized into four groups: 1 3, 4 6, 7 9, and 10 or more. The percent LN positive was stratified into three levels: low, 0.01% to 24%; moderate, 25% to 49%; and high, 50% or higher. This was calculated simply by dividing the number of LNs that were reported as positive in the database by the total number of LNE. These are similar to the groups used in other studies in the literature [12 16]. The prognostic value of a given variable (either the number of LNE or the percentage of LNs that were positive) was assessed using the associated hazard ratio and 95% confidence interval from a multivariate Cox proportional hazards model for overall and diseasespecific survival. Potential confounding variables associated with survival were included in the model to demonstrate that the prognostic effect persists after accounting for the effect of these variables. These included age, race, sex, tumor size, and histologic grade of the tumor. Proportional hazard results were supplemented with Kaplan-Meier survival curves. Table 1. Clinical and Pathologic Patient Characteristics Variables Number of Patients (%) Overall cohort 25,887 (100) Age 70 y 16,080 (62.1) 70 y 9,807 (37.9) White 22,210 (85.8) Black 2,029 (7.8) Other 1,648 (6.4) Sex Male 13,883 (53.6) Female 12,004 (46.4) Stage Localized 15,978 (61.7) Regional 9,909 (38.3) Grade I 3,335 (12.9) II 10,359 (40.0) III 10,759 (41.6) IV 1,434 (5.5) Histology Squamous cell carcinoma 7,701 (29.8) Bronchioloalveolar carcinoma 2,596 (10.1) Adenocarcinoma 11,254 (43.6) Other 4,252 (16.5) Surgery Lobectomy 24,521 (95.1) Pneumonectomy 1,277 (4.9) Nodal stage (where available) N0 2,891 (81.6) N1 531 (15.0) N2 120 (3.4) 1 3 6,764 (26.1) 4 6 7,144 (27.6) 7 9 4,782 (18.5) 10 7,197 (27.8) Node positivity ratio 0.01% to 24% 2,355 (47) 25% to 49% 1,231 (24.6) 50% or higher 1,426 (28.4) Survival status Alive 10,661 (41.2) Dead 15,226 (58.8) Follow-up (mo), median (range) ( ) Results The total number of patients who met the eligibility criteria was 25,887; of these, 15,978 had localized disease and 9,909 had regional disease. Demographic, surgical treatment, and histopathologic characteristics of the entire cohort (including distribution of the LN categories) are listed in Table 1. The mean tumor size was 34 mm. The median follow-up time for the entire cohort was 48 months. A small proportion of the whole cohort (3,568 patients) had TNM staging information, and their median follow-up time was 20 months. The number of LNE had greater prognostic value for disease-specific and overall survival in patients with localized disease than in those with regional disease (Tables 2, 3). Fewer LNE corresponded with a worse prognosis. The median number of LNE was 6. Prognosis improved as more LNs were examined. In patients with positive LNs, the LNR was associated with disease-

3 1616 NWOGU ET AL Ann Thorac Surg LYMPH NODE NUMBER/RATIO IN LUNG CANCER 2012;93: Table 2. Cox Proportional Hazards Model for Overall Survival Variable Localized Disease (n 15,978) HR (95% CI) p Value Regional Disease (n 9,909) HR (95% CI) p Value ( ) ( ) ( ) ( ) ( ) ( ) % Nodes positive 0.01% 24% (n 2,355) 0.51 ( ) % 49% (n 1,231) 0.68 ( ) % 100% (n 1,426) 1.0 Age at diagnosis (per year) 1.04 ( ) ( ) White Black 1.13 ( ) ( ) 0.39 Other 0.77 ( ) ( ) 0.29 Sex (female versus male) 0.70 ( ) ( ) Histologic grade Grade I Grade II 1.32 ( ) ( ) Grade III 1.57 ( ) ( ) Grade IV 1.58 ( ) ( ) Tumor size (mm) 1.00 ( ) ( ) CI confidence interval; HR hazard ratio. specific and overall survival. Patients with low (0.01% to 24%) or moderate (25% to 49%) LNRs had better prognoses than those with high (50% or higher) LNRs (Figs 1, 2). This statistically significant association between LNR and overall survival was maintained even when unadjusted Kaplan-Meier survival curves were analyzed for the different LNE groupings (1 3, 4 7, 7 9, and 10 ). In the subset of patients with American Joint Committee on Cancer nodal staging information, the number of LNE was not prognostic, but LNR was prognostic for both disease-specific and overall survival in patients with N1 and N2 disease (Table 4). The odds of having at least one malignant LN increased with the number of LNE. Compared with patients with 1 to 3 LNE, the odds ratio for 4 to 6, 7 to 9, and 10 or more LNE were 1.57 (range, 1.42, 1.73), 2.02 (range, 1.82, 2.23), and 2.81 (range, 2.57, 3.07), respectively. The probability values were all less than Younger age, lower grade disease, smaller tumor size, and female sex were associated with better diseasespecific and overall survival (Tables 2 4). was not a consistent independent predictor of survival. Comment In this study, we analyzed data from the SEER database to determine the influence of number of LNE and the LNR on the survival of all patients with resectable NSCLC. The case ascertainment rate of the SEER registries has been reported to be 97.5%, and it is believed to accurately represent the entire American population [17]. The SEER group currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28% of the US population [18]. It has been shown that the number of LNs evaluated after resection for stage I NSCLC is associated with patient survival [13, 17, 19]. This study examined this association in both localized and regional disease (stages I to III). We also sought to corroborate the findings of others about the prognostic value of the LNR in resectable NSCLC patients [11]. The extent of lymphadenectomy has remained controversial for quite some time, but at a minimum, systematic LN sampling is considered vital for adequate staging [17, 20]. Unfortunately, a large number of patients are inadequately staged [19, 21]. This may negatively impact survival by depriving understaged patients of the potential benefits of adjuvant therapy. The National Comprehensive Cancer Network Guidelines Version for treatment of NSCLC includes recommendations for the sampling of at least three N2 stations or complete mediastinal LN dissection. Formal ipsilateral mediastinal LN dissection for patients undergoing resection for stage IIIA (N2) disease is also recommended [22]. Our study results support the hypothesis that a lower number of LNE and a higher LNR is associated with poorer overall survival from NSCLC. There are several possible explanations for our findings. First, stage migration can certainly occur as more LNs are harvested and pathologically examined, resulting in improved staging accuracy. Some patients who would have otherwise been erroneously included among stage I patients are up-

4 Ann Thorac Surg NWOGU ET AL 2012;93: LYMPH NODE NUMBER/RATIO IN LUNG CANCER 1617 Table 3. Cox Proportional Hazards Model for Disease-Specific Survival Variable Localized Disease (n 15,978) HR (95% CI) p Value Regional Disease (n 9,909) HR (95% CI) p Value ( ) ( ) ( ) ( ) ( ) ( ) % Nodes positive 0.01% 24% (n 2,355) 0.47 ( ) % 49% (n 1,231) 0.67 ( ) % 100% (n 1,426) 1.0 Age at diagnosis (per year) 1.02 ( ) ( ) White Black 1.21 ( ) ( ) 0.64 Other 0.77 ( ) ( Sex (female versus male) 0.77 ( ) ( ) Histologic grade Grade I Grade II 1.37 ( ) ( ) Grade III 1.72 ( ) ( ) Grade IV 1.82 ( ) ( ) Tumor size (mm) 1.00 ( ) ( ) CI confidence interval; HR hazard ratio. staged [12]. The patients who remain in stage I would then have better survival figures. Conversely, patients who migrate to stages II and III with less burden of disease improve the survival for those stages. Second, there is the possibility that a more robust immunologic response in the regional LNs may result in both greater ease of identification or examination of these LNs and improved survival of such patients [23]. Third, there is the potential for therapeutic benefit of systematic lymphadenectomy in a subset of patients who have minimal disease in the LNs without systemic disease. The favorable impact of younger age, lower grade disease, smaller tumor size, and female sex is consistent with established knowledge [3]. There were some unexpected findings from our study. The number of LNE was more prognostic in patients with localized disease than in those with regional disease. This suggests that the differences in survival may be more attributable to stage migration rather than to a therapeutic effect. As more LNs are examined in patients with localized disease, the staging accuracy improves, but once MLNs are detected, the benefit of examining more LNs could be diminished. The LNR was consistently prognostic for overall and disease-specific survival, even in the small subset of patients with TNM staging information. The LNR may thus be more attractive than LNE as a new variable to Fig 1. Unadjusted Kaplan-Meier estimates for disease specific survival in patients with regional disease with at least one positive lymph node (LN). Fig 2. Unadjusted Kaplan-Meier estimates for overall survival in patients with regional disease with at least one positive lymph node (LN).

5 1618 NWOGU ET AL Ann Thorac Surg LYMPH NODE NUMBER/RATIO IN LUNG CANCER 2012;93: Table 4. Cox Proportional Hazards Model for Disease-Specific and Overall Survival in Patients With American Joint Committee on Cancer Nodal Staging Data Variable Disease-Specific Survival HR (95% CI) p Value Overall Survival HR (95% CI) p Value ( ) ( ) ( ) ( ) ( ) ( ) % Nodes positive 0.01% 24% 0.38 ( ) ( ) % 49% 0.56 ( ) ( ) % 100% Age at diagnosis (per year) 1.03 ( ) ( ) White Black 1.05 ( ) ( ) Other 0.91 ( ) ( ) Sex (female versus male) 0.69 ( ) ( ) Histologic grade Grade I Grade II 1.18 ( ) ( ) Grade III 1.83 ( ) ( ) Grade IV 1.59 ( ) ( ) Tumor size (mm) 1.01 ( ) ( ) CI confidence interval; HR hazard ratio. include in the next revision of the staging system. Only 14% of the cohort had TNM staging information because this was not required for SEER database entry until The number of LNE was not prognostic in this group of patients. However, the median follow up for these patients was only 20 months. Sufficient maturity of the data with longer follow-up may be necessary to permit adequate assessment of the value of LNE. A major strength of the SEER data is that the large sample size allows the detection of moderate associations and permits complex multivariate analysis [13]. It is also more generalizable to the community, but it lacks granular detail such as smoking history, performance status, preoperative staging methods (such as positron emission tomography scans), LN level dissected, completeness of resection (R0, R1, or R2), lymphatic or vascular invasion, recurrence patterns, and the use of chemotherapy [17]. Also, the database does not differentiate between intact LNs and nodal fragments. Thus, the number of LNE may have been overestimated in our study. As reported by Ludwig and colleagues [13], if such misclassification is random (ie, not related to survival), this would bias the results toward null. Thus, the true association may be somewhat stronger than what we reported in our study. The American College of Surgeons Oncology Group conducted a large, prospective randomized multicenter study of N0 and nonhilar N1 resectable lung cancer patients (Z0030). One group had systematic LN sampling whereas the other had complete lymphadenectomy. For this subset of patients, there was no difference in survival between the two groups [24]. However, it is must be emphasized that systematic LN sampling entails rigorous identification, resection, and examination of several nodes from a combination of hilar and mediastinal LN stations. This American College of Surgeons Oncology Group study cannot be used as justification to remove an insufficient number of LNs, which would compromise accurate staging of the disease. As the International Association for the Study of Lung Cancer continues to collect prospective data beyond the set used for the recent update in the lung cancer staging system [25], it may become apparent that the addition of number of resected LNs or the LNR will improve our prognostication for NSCLC patients. The International Association for the Study of Lung Cancer database includes patients from several countries and provides more lung cancer specific detail than the SEER database. Thus, it can serve as a great resource to study these LN variables further. This may also facilitate the designation of a minimum number of LNs that must be sampled for the LN staging to be considered adequate. In summary, our study shows that lower number of LNE and higher LNR are both associated with poorer disease-specific and overall survival. This emphasizes the need for ongoing education in the broad surgery and pathology communities about the value of adequate LN assessment.

6 Ann Thorac Surg NWOGU ET AL 2012;93: LYMPH NODE NUMBER/RATIO IN LUNG CANCER 1619 This work was supported by Roswell Park Cancer Institute and National Cancer Institute (NCI) grant number P30 CA References 1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, CA Cancer J Clin 2010;60: Park BJ, Rusch VW. Lung cancer workup and staging. In: Sellke FW, del Nido PJ, Swanson SJ, eds. Surgery of the chest, 7th ed. Philadelphia, PA: Elsevier; 2005: Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to Cancer 2007;110: Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer; Peschaud F, Benoist S, Julié C, et al. The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg 2008;248: Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245: Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res 2004;6:R Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003;169: Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23: Bria E, Milella M, Sperduti I, et al. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer 2009;66: Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003;21: Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005;128: Fukui T, Mori S, Yokoi K, Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006;1: Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 2008;85: Wisnivesky JP, Arciniega J, Mhango G, Mandeli J, Halm EA. Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax 2011;66: Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009;115: Overview of the SEER program. Available at seer.cancer.gov/about/overview.html. Accessed January 11, Osarogiagbon RU, Allen JW, Farooq A, Berry A, O Brien T. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Ann Thorac Surg 2011;91: Rami-Porta R, Wittekind C, Goldstraw P, International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005;49: Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80: Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8: Takenoyama M, Yasumoto K, Harada M, Sugimachi K, Nomoto K. Antitumor response of regional lymph node lymphocytes in human lung cancer. Cancer Immunol Immunother 1998;47: Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non small cell carcinoma: Results of the american college of surgery oncology group Z0030 trial. J Thorac Cardiovasc Surg 2011;141: Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2: DISCUSSION DR ROBERT J. CERFOLIO (Birmingham, AL): Well, again, the SEER (Surveillance, Epidemiology and End Results) database, let s not get back into talking about SEER, but let s just talk in general. So the ACOSOG (American College of Surgeons Oncology Group) study, of course, was set to accrue patients that were node negative and randomized. And that s why I didn t participate in the study, because if you are going to fix the game before the game starts, why play the game? You know if you look at patients who are node negative, in the right chest in ACOSOG Z0030 you had to be node negative in the 4R, 7, and the and in the left chest it was 5, 6, and 7 after rigorous lymph node sampling. So obviously you are selecting out patients that are almost certainly N2 negative. So of course taking more N2 nodes in these patients will be unlikely to find a difference but even in these patients they reported a trend towards a higher median survival. But the more important part is taking all the lymph nodes and how do we count them? You and I know we can take one lymph node out of the 4R, put it on the back table and cut it 10 times and say here s a 2R, here s a 7, here s an 8, here s a 9. That s the problem. The problem is the majority of surgeons that do this surgery aren t general thoracic surgeons. They do a thoracotomy and you see the pathology report and there s one lymph node removed and it is labeled lymph node no number, nothing. So I think that we need to do a better job. We need to insist and ask the surgeon to place a clip in the 2R station, the 4R station, 7, 8, and 9 to document that the surgeon was at least there and removed those nodes, because the number and the amount can be fudged. And I think in order for surgeons to get paid, that s when we should mandate the postoperative chest x-ray that shows a little clip on the right side in stations 2R, 4, 7, 8, and 9, and in the left chest, 5, 6, 7, 8, 9, and 4L if you can get there. DR DANIEL L. MILLER (Atlanta, GA): Just like you, we reviewed the SEER database. At Emory, we reviewed patients who underwent complete resections for early stage disease, no lymph

7 1620 NWOGU ET AL Ann Thorac Surg LYMPH NODE NUMBER/RATIO IN LUNG CANCER 2012;93: node involvement, and had lymph nodes removed. We found that if you removed at least 13 to 16 lymph nodes, survival was improved, which translated into better intraoperative staging. The problem in your series is that you have a patient heterogeneity related to the type of resection, complete and incomplete. Therefore, this is a major problem. So for you to clean this up, I think it is going to require a lot of work, you will need to redo the analysis based on completeness of resection. I feel that the ratio is a different problem, as Cerf suggested, in regards to your pathologists. DR J. ROBERT HEADRICK (Chattanooga, TN): My question is in regards to how you counted lymph nodes. We found that when we performed a minimally invasive node dissection more of the nodes were fragmented. Our pathologists were counting the fragments as separate nodes, artificially elevating the node count at each station. Can you explain a little bit more about how you counted your lymph nodes and what constituted a lymph node? DR NWOGU: I think I can address a number of the questions. I think we all agree that there are some challenges with the ACOSOG study. It is not applicable to all the patients that we see. But what I wanted to highlight, but didn t really get enough time to discuss, is that some surgeons in the community may now use this as an excuse not to assess a sufficient number of lymph nodes. There are prominent limitations with the SEER database, especially for looking at stages 1 through 3 NSCLC (non small cell lung carcinoma). I think that is where we could use the International Association for the Study of Lung Cancer (IASLC). Their database is much more robust than SEER. It could be used to assess whether these variables (LNR [lymph node ratio] and LNE [lymph nodes examined]) are truly relevant. And in terms of counting the number of nodes, that is definitely a challenge, but I don t see an easy way to get around it in terms of the pathologic assessment. It is important that we label the nodes appropriately so that the pathologists have the ability to give us the information that we need. DR SETH D. FORCE (Atlanta, GA): I just wondered again, with regards to your study, do you look at the ratio of positive lymph nodes? Can you stratify that by number of lymph nodes removed? When you look at ratios, do you just look at all lymph nodes removed? DR NWOGU: We looked at all lymph nodes. DR FORCE: You need to look at the lymph node ratio per the number of lymph nodes removed, because if you take a patient who has one lymph node removed and it is positive, that is a 100%, right? So I think you are going to have to go back and look at the number of lymph nodes removed and perform the ratio there to figure that out, and even try to define it as a minimum number of nodes you need to remove to make your paper more meaningful. DR JOSHUA ROBERT SONETT (New York, NY): And that s in the context of the SEER database. You need to do that in your own database. In the SEER database, as you say, garbage in, garbage out. But this type of accurate assessment, looking at the SEER database, I suspect is not all that helpful. DR FORCE: It is not a theoretical problem, because we are just going to look at the data itself. Can you really include patients who had one or two lymph nodes removed? You shouldn t even include those, because they are going to throw off your results.

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer

Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer

Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer See Editorial, p 271 1 Divisions of General Internal Medicine, Mount Sinai School of Medicine, New York, New York, USA 2 Division of Pulmonary, Critical Care, and Sleep Medicine, Mount Sinai School of

More information

Only about 16% of the approximately 200,000 persons

Only about 16% of the approximately 200,000 persons GENERAL THORACIC Nonexamination of Lymph Nodes and Survival After Resection of Non-Small Cell Lung Cancer Raymond U. Osarogiagbon, MBBS, and Xinhua Yu, MD, PhD Multidisciplinary Thoracic Oncology Program,

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer European Journal of Cardio-Thoracic Surgery 49 (2016) 580 588 doi:10.1093/ejcts/ezv134 Advance Access publication 18 April 2015 ORIGINAL ARTICLE Cite this article as: Lee GD, Kim DK, Moon DH, Joo S, Hwang

More information

Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes

Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes Pawełczyk et al. Journal of Cardiothoracic Surgery (2016) 11:68 DOI 10.1186/s13019-016-0456-5 RESEARCH ARTICLE Open Access Evaluation of new classifications of N descriptor in non-small cell lung cancer

More information

Lymph node ratio as a prognostic factor in stage III colon cancer

Lymph node ratio as a prognostic factor in stage III colon cancer Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter?

State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Review Article State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Laura Romero Vielva 1, Manuel Wong Jaen 1, José A. Maestre Alcácer 2, Mecedes Canela Cardona

More information

Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database

Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Lung cancer is the leading cause of cancer deaths worldwide.

Lung cancer is the leading cause of cancer deaths worldwide. ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy

Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy CHEST Original Research Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial LUNG CANCER Gail

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,

More information

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Small-cell lung cancer (SCLC) represents approximately

Small-cell lung cancer (SCLC) represents approximately Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,

More information

Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy

Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy International Surgical Oncology Volume 2012, Article ID 307670, 7 pages doi:10.1155/2012/307670 Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

More information

Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer

Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer Hou et al. World Journal of Surgical Oncology (2018) 16:198 https://doi.org/10.1186/s12957-018-1504-5 REVIEW Open Access Prognostic significance of metastatic lymph node ratio: the lymph node ratio could

More information

Lung cancer involving neighboring structures is classified

Lung cancer involving neighboring structures is classified GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,

More information

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,

More information

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce

More information

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Postoperative Mortality in Lung Cancer Patients

Postoperative Mortality in Lung Cancer Patients Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons

A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT

More information

Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection

Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen

More information

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical

More information

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Carcinoma of the Lung in Women

Carcinoma of the Lung in Women Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Despite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer

Despite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,

More information

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article.

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article. Original Article Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes Xing Wang *,

More information

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University

More information

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD

More information

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

The T4 category of lung cancer is defined by invasion of the

The T4 category of lung cancer is defined by invasion of the Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,

More information

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC 8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour

More information

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in 1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the

More information

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis

More information

Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery

Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery Ann Surg Oncol (2011) 18:603 607 DOI 10.1245/s10434-010-1442-0 EDITORIAL Local and Systemic Recurrence is the Achilles Heel of Cancer Louis A. Aliperti 1, Jarrod D. Predina 1, Anil Vachani 2, and Sunil

More information

Lung cancer kills more people than breast, colon, and

Lung cancer kills more people than breast, colon, and ORIGINAL ARTICLE Clinical Characteristics and Survival of Patients with Surgically Resected, Incidentally Detected Lung Cancer Dan J. Raz, MD,* David V. Glidden, PhD, Anobel Y. Odisho, BA, and David M.

More information

Multifocal Lung Cancer

Multifocal Lung Cancer Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department

More information

Differential lymph node retrieval in rectal cancer: associated factors and effect on survival

Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic

More information

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy

More information

Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014

Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected

More information

Sagar Damle, MD University of Colorado Denver May 23, 2011

Sagar Damle, MD University of Colorado Denver May 23, 2011 Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

More information

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,

More information

Selective lymph node dissection in early-stage non-small cell lung cancer

Selective lymph node dissection in early-stage non-small cell lung cancer Review Article Selective lymph node dissection in early-stage non-small cell lung cancer Han Han 1,2, Haiquan Chen 1,2 1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai

More information

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental

More information

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Original Article Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Hiroaki Kuroda 1,2, Yukinori Sakao 1,2, Mingyon Mun 2, Noriko Motoi 3, Yuichi Ishikawa 3, Ken

More information

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco

More information

Chapter 13 Cancer of the Female Breast

Chapter 13 Cancer of the Female Breast Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results

More information

Mauricio Camus Appuhn Associate Professor Chief, Department of Surgical Oncology, Pontificia Universidad Católica de Chile

Mauricio Camus Appuhn Associate Professor Chief, Department of Surgical Oncology, Pontificia Universidad Católica de Chile May 18-20, 2017 18 a 20 de Maio / 2017 Castro's Park Hotel Surgery for metastatic breast cancer: the controversy of local surgery for metastatic breast cancer Cirurgia em câncer de mama metastático: a

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information